« Zurück
Startseite /
Avibactam (free acid)

Avibactam (free acid)

ArtNr	HY-14879-10mM
Hersteller	MedChem Express
CAS-Nr.	1192500-31-4
Menge	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.22
Citations	[1]Ehmann DE, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8.\|[2]Livermore DM, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012 Jun;67(6):1354-8.\|[3]Berkhout J, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304.\|[4]Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142. Antibiotics (Basel). 2023 Jul 20, 12(7), 1212.\|Antibiotics (Basel). 2024 May 1, 13(5), 416.\|Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02260-16.\|Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01809-18.\|Antimicrob Agents Chemother. 2019 Aug 23;63(9):e01374-19.\|Antimicrob Agents Chemother. 2019 Sep 16;63(12):e01515-19.\|Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02025-19.\|Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00409-20.\|Antimicrob Agents Chemother. 2023 May 18;e0160322.\|Antimicrob Agents Chemother. 2023 May 31;e0033923.\|Antimicrob Agents Chemother. 2023 Sep 6;e0052823.\|Antimicrob Agents Chemother. 2023 Sep 8;e0030123.\|Antimicrob Agents Chemother. 2024 Oct 4:e0077524.\|Biomed Res Int. 2018 Jul 2;2018:3579832. \|BMC Microbiol. 2020 Jun 29;20(1):187.\|BMC Microbiol. 2019 Nov 1;19(1):240.\|Eur J Clin Microbiol Infect Dis. 2024 Dec 20.\|Eur J Clin Microbiol Infect Dis. 2024 Nov 26.\|Int J Med Microbiol. 2020 Jul;69(7):928-931.\|J Antimicrob Chemother. 2017 Jul 1;72(7):1930-1936.\|J Antimicrob Chemother. 2017 Sep 1;72(9):2483-2488.\|J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615.\|J Antimicrob Chemother. 2024 Apr 2:dkae097.\|J Clin Microbiol. 2023 Apr 18;e0164722.\|Microb Drug Resist. 2020 Apr;26(4):334-340.\|Microbiol Spectr. 2023 Apr 24;e0069223.\|Preprints. 2023 Jun 21.\|ACS Infect Dis. 2021 Jun 30.\|Acta Microbiol Immunol Hung. 2021 Jul 29.\|Adv Ther (Weinh). 2024 Jan 12.\|Antibiotics (Basel). 2021 Sep 14;10(9):1110.\|Antibiotics (Basel). 2021, 10(11), 1341.\|Antibiotics (Basel). 2022, 11(10), 1280.\|Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18. \|Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00433-18.\|Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18. \|Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00873-18.\|Antimicrob Agents Chemother. 2022 Jun 1;e0240221.\|Antimicrob Agents Chemother. 2023 Jan 23;e0145922.\|bioRxiv. 2021 Mar 13.\|bioRxiv. 2024 Sep 25:2024.09.25.615047.\|Biosens Bioelectron. 2021 Jul 21;193:113526.\|Cell Rep. 2024 Nov 9;43(11):114962.\|Infect Drug Resist. 2020 Aug 18;13:2883-2890.\|Infect Drug Resist. 2021 Jun 30;14:2499-2507.\|Int J Antimicrob Agents. 2018 Aug;52(2):269-271.\|Int J Antimicrob Agents. 2024 Jun 24:107256.\|Int J Antimicrob Agents. 2024 May 14:107206.\|Int J Infect Dis. 2020 Apr;93:252-257. \|Int J Med Microbiol. 2021 Oct;70(10).\|Int J Mol Sci. 2021, 22(6), 3051.\|J Antimicrob Chemother. 2021 Feb 11;76(3):653-658.\|J Antimicrob Chemother. 2021 May 6;dkab141.\|J Antimicrob Chemother. 2022 Jul 15;dkac232.\|J Antimicrob Chemother. 2023 Feb 13;dkad032.\|J Infect Dev Ctries. 2021 Mar 31;15(3):404-414.\|J Infect Dis. 2019 Jul 2;220(3):484-493. \|Microbiol Spectr. 2022 Aug 16;e0139022.\|Microbiol Spectr. 2022 Aug 24;e0203522.\|Microbiol Spectr. 2022 Dec 8;e0303822.\|Microbiol Spectr. 2023 Nov 20:e0304723.\|Microbiol Spectr. 2024 Sep 3.\|Molecules. 2025 Mar 9;30(6):1224.\|Nature. 2024 Aug;632(8026):893-902.\|Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611.\|PLoS Pathog. 2024 Dec 31;20(12):e1012783.\|RSC Adv. 2023 Nov 30;13(49):34884-34890.\|Sci Rep. 2022 Oct 7;12(1):16814.\|Int J Infect Dis. 2021 Apr 14;S1201-9712(21)00346-5.\|J Clin Microbiol. 2020 Aug 24;58(9):e00932-20.
Smiles	O=S(ON1[C@]2([H])CC[C@@H](C(N)=O)[N@@](C2)C1=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NXL-104 (free acid)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Antibiotic; Bacterial; Beta-lactamase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	265.24
Product Description	Avibactam (NXL-104) free acid is a covalent and reversible non-β-lactam β-lactamase inhibitor which inhibits β-lactamase TEM-1 and CTX-M-15 with IC50s of 8 nM and 5 nM, respectively[1].
Manufacturer - Research Area	Infection
Solubility	DMSO: 125 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-14879-10mM-safety-datasheet.pdf